文献速递胸部肿瘤放疗

III期非小细胞肺癌个体化加速等毒合并放化疗:一项前瞻性研究的5年结果

Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.
PubMed 文献 · Radiother Oncol · 2019-03-27

这项前瞻性研究纳入185例适合合并放化疗的III期非小细胞肺癌患者,采用个体化加速等毒剂量递增(INDAR)联合IMRT及合并化疗。中位总生存期为19.8个月(95%CI 17.3-22.3),5年总生存率为24.3%。结论认为,在未经选择的III期NSCLC患者中,INDAR联合IMRT合并化疗未显示出总生存改善的迹象。

要点

  • 185例III期NSCLC患者接受INDAR联合IMRT及合并化疗,中位总生存期19.8个月。
  • 5年总生存率为24.3%,局部区域失败作为首次复发部位见于59/185例(31.8%)。
  • 结论认为该方案在未经选择的III期NSCLC患者中未显示总生存改善的迹象。

核心结论

  • 在未经选择的III期NSCLC患者中,INDAR联合IMRT合并化疗未显示出总生存改善的迹象。

研究设计与样本

  • 前瞻性研究,纳入适合合并放化疗的III期NSCLC患者185例,自2009年5月4日至2012年4月26日入组。
  • 放疗方案为45 Gy/30次,每日两次(1.5 Gy/次),随后每日一次2 Gy,直至根据正常组织约束确定的总剂量。
  • 主要终点为总生存期,次要终点为局部区域复发和毒性。

主要发现

  • 平均肿瘤剂量为66.0±12.8 Gy(范围36-73 Gy),平均39.7次,总治疗时间38.2天。
  • 平均肺剂量(MLD)为17.3 Gy。
  • 中位总生存期为19.8个月(95%CI 17.3-22.3),5年总生存率为24.3%。
  • 局部区域失败作为首次复发部位见于59/185例(31.8%),孤立淋巴结失败见于3/185例(1.6%)。
  • 3级呼吸困难见于3.2%的患者,一过性3级吞咽困难见于22%的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stage III non-small cell lung cancer (NSCLC) still has a poor prognosis. Prior studies with individualized, accelerated, isotoxic dose escalation (INDAR) with 3D-CRT showed promising results, especially in patients not treated with concurrent chemo-radiotherapy. We investigated if INDAR delivered with IMRT would improve the overall survival (OS) of stage III NSCLC patients treated with concurrent chemotherapy and radiotherapy. PATIENTS AND METHODS: Patients eligible for concurrent chemo-radiotherapy were entered in this prospective study. Radiotherapy was given to a dose of 45 Gy/30 fractions BID (1.5 Gy/fraction), followed by QD fractions of 2 Gy until a total dose determined by the normal tissue constraints. The primary endpoint was OS, secondary endpoints were loco-regional relapses and toxicity. RESULTS: From May 4, 2009 until April 26, 2012, 185 patients were included. The mean tumor dose was 66.0 ± 12.8 Gy (36-73 Gy), delivered in a mean of 39.7 fractions in an overall treatment time of 38.2 days. The mean lung dose (MLD) was 17.3 Gy. The median OS was 19.8 months (95% CI 17.3-22.3) with a 5-year OS of 24.3%. Loco-regional failures as first site of recurrence occurred in 59/185 patients (31.8%). Isolated nodal failures (INF) were observed in 3/185 patients (1.6%). Dyspnea grade 3 was seen in 3.2% of patients and transient dysphagia grade 3 in 22%. CONCLUSIONS: INDAR with IMRT concurrently with chemotherapy did not lead to a sign of an improved OS in unselected stage III NSCLC patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. De Ruysscher D, van Baardwijk A, Wanders R, et al. Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. Radiother Oncol. 2019. PMID: 31015160. doi:10.1016/j.radonc.2019.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。